Physician

Samuel E Myrick, MD

According to 2025 Medicare claims, Samuel Myrick, MD (NPI: 1831180546) practices medical oncology in the Ocala, FL market, with the plurality of this provider's patient population coming from Marion, FL. This provider's primary affiliated billing organization is OCALA ONCOLOGY CENTER PL (NPI: 1356300958; TIN: 900336929) and primary practice location at 34474-4445. Myrick is affiliated with the Primary Care Alliance, LLC (ACO ID: D0010), participating under the REACH model.

Myrick's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 727 traditional Medicare patients, billed 175,661 HCPCS/CPT codes, and received $2,743,720 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,010 prescription claims across 212 beneficiaries totaling $2,614,178 in drug costs, led by Erleada (Apalutamide). 2022 DME data shows 26 claims. Open Payments data shows 243 records totaling $6,574. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,421,174 and ending at $2,743,720. Concurrently, Part D prescription costs have risen steadily, from $581,962 to $2,614,178. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	669	108,653	$1,421,174
2016	987	163,190	$2,244,652
2017	949	193,595	$2,174,940
2018	861	174,534	$1,903,659
2019	962	249,319	$2,601,969
2020	788	235,562	$2,353,002
2021	711	191,418	$1,842,125
2022	705	151,318	$1,970,152
2023	688	152,186	$1,778,793
2024	727	175,661	$2,743,720

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	126	648	$581,962
2016	188	872	$1,179,114
2017	215	1,154	$1,550,792
2018	224	1,187	$1,691,231
2019	213	998	$1,778,358
2020	242	1,181	$1,724,682
2021	203	1,107	$2,288,097
2022	200	944	$2,308,858
2023	204	936	$1,983,315
2024	212	1,010	$2,614,178

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	80	$34,269
2016	12	165	$46,052
2017	N/R	166	$44,193
2018	N/R	137	$14,439
2019	13	133	$22,413
2020	N/R	90	$20,034
2021	N/R	84	$4,116
2022	N/R	26	$690
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	210	436	$100
96372	Injection of drug or substance under skin or into muscle	203	395	$11
80053	Blood test, comprehensive group of blood chemicals	265	781	$10
36415	Insertion of needle into vein for collection of blood sample	272	841	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	274	878	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	20	780	$372,462
Imbruvica	Ibrutinib	21	588	$337,587
Lenvima	Lenvatinib Mesylate	12	360	$291,709
Xtandi	Enzalutamide	13	390	$182,919
Lenalidomide	Lenalidomide	19	532	$157,992

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	243	$6,574	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Samuel E. Myrick, MD?

Tedicare shows public-source Medicare data for Samuel E. Myrick, MD (NPI 1831180546), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Samuel E. Myrick, MD have ACO affiliation data?

Samuel E. Myrick, MD is shown with ACO affiliation data for Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Samuel E. Myrick, MD?

Samuel E. Myrick, MD is linked to OCALA ONCOLOGY CENTER PL (billing NPI 1356300958) in the available physician profile data.

Does Samuel E. Myrick, MD have Open Payments data?

Samuel E. Myrick, MD has 243 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.